GlassScriptPhysician profile
Scott M Leibowitz
NPI 1184618100
$21,584.60
in general payments reported to CMS, 2019-2025
15 companies · $9,718 in 2025
The $9,718 reported for 2025 was more than what 95% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $18.33 · 2021: $2,344 · 2022: $5,290 · 2023: $2,050 · 2024: $1,893 · 2025: $9,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,364 · Consulting Fee: $3,921 · Travel and Lodging: $978 · Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,364.00 |
| Consulting Fee | $3,921.00 |
| Travel and Lodging | $978.03 |
| Food and Beverage | $397.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $12,566.34 | 2019-2025 | |
| Harmony Biosciences LLC | $7,994.99 | 2020-2024 | Wakix |
| Supernus Pharmaceuticals, INC. | $634.39 | 2021-2023 | Qelbree |
| Intuitive Surgical, INC. | $89.97 | 2019 | |
| Ucb, INC. | $71.33 | 2019-2022 | |
| Genzyme Corporation | $39.61 | 2019 | |
| Neurocrine Biosciences, INC. | $37.71 | 2025 | |
| Amgen INC. | $27.49 | 2019 | |
| Merz Pharmaceuticals, LLC | $23.52 | 2021 | |
| Boston Scientific Corporation | $21.92 | 2025 | General - Pain Management |
| Avanir Pharmaceuticals, INC. | $20.76 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.86 | 2019 | |
| Abbvie INC. | $16.78 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.69 | 2023 | Austedo Xr |
| Aucta Pharmaceuticals, INC. | $7.24 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.